Last updated on March 2009

Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab

Brief description of study

The study is designed to demonstrate the therapeutic non-inferiority of the recombinant humanized monoclonal VEGF antibody bevacizumab administered by intravitreal injection in the treatment of AMD in comparison to the related fragment ranibizumab.

Clinical Study Identifier: NCT00559715

Contact Investigators or Research Sites near you

Start Over

Bernd Muehlbauer, Professor MD

Department of Pharmacology at Klinikum Bremen Mitte
Bremen, Germany
  Connect »